TIANJINJINRAN (01265) announced its annual performance with a net loss attributable to shareholders of RMB 44.2464 million, a decrease of 4.5% year-on-year.
Tianjin Tianran Public Utilities (01265) released its annual performance for 2025, with operating income of 1.592 billion yuan, a 0.2% decrease year-on-year. The net loss attributable to shareholders of the parent company was 44.2464 million yuan, a 4.5% decrease year-on-year, with a basic loss per share of 0.024 yuan.
TIANJINJINRAN (01265) announced its performance for the year 2025, with operating income of 1.592 billion yuan, a year-on-year decrease of 0.2%; a net loss attributable to shareholders of the parent company of 44.2464 million yuan, a year-on-year narrowing of 4.5%; basic loss per share of 0.024 yuan.
The announcement stated that during the reporting period, the gross profit margin and total profit slightly increased compared to last year, mainly due to the decrease in international natural gas prices, which resulted in a decrease in the gas source settlement price of the upstream gas source unit Jinran CHINA RES GAS Co., Ltd.
Related Articles

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

HKT-SS (06823) sold approximately US$209 million for 9% equity interest in Regional Link Telecom Services Holdings Limited.

CNBM(03323): Tianshan Materials(000877.SZ) is expected to have a net loss attributable to shareholders of approximately 7.291 billion yuan in 2025, an increase of approximately 9.16 times year-on-year.
SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

HKT-SS (06823) sold approximately US$209 million for 9% equity interest in Regional Link Telecom Services Holdings Limited.

CNBM(03323): Tianshan Materials(000877.SZ) is expected to have a net loss attributable to shareholders of approximately 7.291 billion yuan in 2025, an increase of approximately 9.16 times year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


